Cara Therapeutics Inc’s (NASDAQ:CARA) Sentiment is 0.83

July 12, 2018 - By Dolores Ford

Cara Therapeutics, Inc. (NASDAQ:CARA) Logo

Sentiment for Cara Therapeutics Inc (NASDAQ:CARA)

Cara Therapeutics Inc (NASDAQ:CARA) institutional sentiment decreased to 0.83 in 2018 Q1. Its down -0.10, from 0.93 in 2017Q4. The ratio fall, as 33 investment professionals opened new or increased holdings, while 40 trimmed and sold positions in Cara Therapeutics Inc. The investment professionals in our partner’s database now possess: 15.62 million shares, down from 15.80 million shares in 2017Q4. Also, the number of investment professionals holding Cara Therapeutics Inc in their top 10 holdings was flat from 1 to 1 for the same number . Sold All: 13 Reduced: 27 Increased: 18 New Position: 15.

Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors in the United States. The company has market cap of $703.70 million. It is developing product candidates that target the body's peripheral nervous system. It currently has negative earnings. The companyÂ’s lead product candidate comprises I.V.

The stock increased 3.86% or $0.8 during the last trading session, reaching $21.52. About 1.18 million shares traded. Cara Therapeutics, Inc. (NASDAQ:CARA) has risen 1.86% since July 12, 2017 and is uptrending. It has underperformed by 10.71% the S&P500.

Analysts await Cara Therapeutics, Inc. (NASDAQ:CARA) to report earnings on August, 2. They expect $-0.51 earnings per share, down 75.86 % or $0.22 from last year’s $-0.29 per share. After $-0.51 actual earnings per share reported by Cara Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 0.00 % EPS growth.

Rho Capital Partners Inc holds 62.3% of its portfolio in Cara Therapeutics, Inc. for 3.57 million shares. Dafna Capital Management Llc owns 93,800 shares or 0.56% of their US portfolio. Moreover, Disciplined Growth Investors Inc Mn has 0.21% invested in the company for 859,565 shares. The Virgin Islands – British-based Shanda Asset Management Holdings Ltd has invested 0.11% in the stock. Baldwin Brothers Inc Ma, a Massachusetts-based fund reported 23,354 shares.

Since January 1, 0001, it had 0 buys, and 7 insider sales for $778,740 activity.

Cara Therapeutics, Inc. (NASDAQ:CARA) Ratings Coverage

Ratings analysis reveals 100% of Cara Therapeutics’s analysts are positive. Out of 5 Wall Street analysts rating Cara Therapeutics, 5 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $22 while the high is $27. The stock’s average target of $24 is 11.52% above today’s ($21.52) share price. CARA was included in 9 notes of analysts from January 19, 2018. Canaccord Genuity maintained it with “Buy” rating and $22 target in Friday, June 29 report. Laidlaw maintained Cara Therapeutics, Inc. (NASDAQ:CARA) on Thursday, May 24 with “Buy” rating. The stock has “Buy” rating by Canaccord Genuity on Thursday, March 15. The firm has “Buy” rating given on Monday, February 12 by Janney Capital. H.C. Wainwright maintained Cara Therapeutics, Inc. (NASDAQ:CARA) on Monday, March 19 with “Buy” rating. The stock has “Buy” rating by H.C. Wainwright on Monday, March 12. The firm earned “Buy” rating on Wednesday, May 23 by H.C. Wainwright. H.C. Wainwright maintained it with “Buy” rating and $2200 target in Friday, May 11 report.

More notable recent Cara Therapeutics, Inc. (NASDAQ:CARA) news were published by: Nasdaq.com which released: “Mid-Afternoon Market Update: US Stocks Turn Negative; Cara Therapeutics Shares Spike Higher” on June 27, 2018, also Streetinsider.com with their article: “Cara Therapeutics (CARA) Announces Dosing of Patients in Phase 2 Trial of Oral KORSUVA for Pruritus in Stage III-V …” published on July 11, 2018, Seekingalpha.com published: “Cara Therapeutics: Worth Keeping An Eye On” on June 28, 2018. More interesting news about Cara Therapeutics, Inc. (NASDAQ:CARA) were released by: Seekingalpha.com and their article: “Cara Therapeutics: Scratching An Itch Left Unscratched” published on June 27, 2018 as well as Streetinsider.com‘s news article titled: “Pre-Open Movers 06/27: (DFBG) (CARA) (I) Higher; (AQXP) (PTIE) (DRRX) Lower (more…)” with publication date: June 27, 2018.

Cara Therapeutics, Inc. (NASDAQ:CARA) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

>